Med-Fine Family | Kehui Zhiyao Announces Successful Completion of Phase I Clinical Trial for ARD-885

This study is a randomized, double-blind, placebo-controlled single and multiple ascending dose trial.Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effects of ARD-885 Tablets in Healthy Chinese Subjects.The study explored8A single dose administration and3Multiple administrations of a single dose, the last oneHealthSubjectAlreadyIn8Month14DayCompleted the research successfullyOut of Group.

ArtivilaTeamThe Phase I clinical trial results of ARD-885 are encouraging, showing good safety and tolerability in healthy subjects, with no serious adverse events reported in any of the subjects during the study period; PK data indicates that ARD-885 has good human exposure and a linear dose relationship; PD data shows that ARD-885 is able toSignificantly inhibits the release of multiple pro-inflammatory cytokines, demonstrating its great potential in anti-inflammatory effects.

ThePhase I clinical trial results were positive and met expectations, supporting the advancement of ARD-885 into the next stage of Phase II clinical research. Artivila has now initiated preparations for the Phase II clinical study, with rheumatoid arthritis as the lead indication. The company is also actively expanding the indications to other autoimmune/inflammatory diseases. Artivila will accelerate the clinical development of ARD-885, aiming to bring this novel and improved treatment option to patients worldwide as soon as possible.

Artivila has a rich pipeline of innovative products and is actively seeking various forms of BD cooperation (such as overseas licensing-out, co-development...ent, etc.), to accelerate the rapid advancement of the first pipeline and expand other significant pipelines, enhancing the overall strength of the company.

About ARD-885

ARD-885 is a dual-target inhibitor Class 1 new drug developed by Artivila, targeting both IRAK4 and IRAK1. Its in vivo and in vitro efficacy surpasses that of similar single-target drugs, making it one of Artivila's core products.AsThe First Product SimultaneouslyTargetedIRAK4AndIRAK1'sDual TargetsSmall MoleculeA New Class 1 Autoimmune Drug, ARD-885, Shows PromiseForRheumatoid arthritis, systemic lupus erythematosus and other immune/Inflammatory DiseasesPatients provide aBrand NewTreatment Strategy。

About Artivila

Artivila is a company focused on using artificial intelligence (Artivila Biopharma is a biotechnology company empowered by an AI platform to drive innovative pharmaceutical R&D. Its unique data and computation-driven drug discovery platform (AI+HI) integrates artificial intelligence, cloud computing, cheminformatics, bioinformatics, drug design, and the team's extensive industry experience, significantly reducing R&D costs and shortening the R&D cycle. The company has an integrated Al/CADD R&D system and an international team led by top scientists. The R&D mainly focuses on autoimmune diseases, neurodegenerative diseases, and cancer. Artivila currently has five targeted innovative drugs in its pipeline that have entered the preclinical/clinical stage, and it has filed more than 60 Chinese and global invention patent applications.

Artivila Has Raised Nearly300 million yuan, gaining recognition from numerous biopharmaceutical professional investors and comprehensive funds, providing a solid guarantee for the company's rapid and steady development. The company's research projects and platform technologies have also received recognition and support from multiple parties and have won awards in innovation and entrepreneurship competitions many times, including the Excellent Enterprise Award of China Innovation and Entrepreneurship Competition and "Top 50 Innovative Enterprises in China."、"Longgang Dual Innovation Star" Biomedical Innovation and Entrepreneurship Competition - First Prize、“Shenzhen CityMaker China"And" Specialized and Innovative Enterprises Innovation and Entrepreneurship CompetitionFirst Prizeetc.

Artivila, Diligent and Innovative, Committed to Changing the Fate of Patients Worldwide!